FDA's Tally: 730+ Adverse-Event Reports Tied to Compounded Tirzepatide (through May 31, 2026)

A number started circulating in mid-2026 that belongs in every compounded-tirzepatide conversation, with its caveats attached: the FDA's count of adverse-event reports associated with compounded tirzepatide exceeded 730 as of May 31, 2026.

The caveats are real. Adverse-event reports are raw signals — unverified, causally unadjudicated, and denominator-free (nobody knows precisely how many patients use compounded product). The approved products generate reports too, at the scale of millions of users, inside a pharmacovigilance system built for the purpose. A report count is not a risk rate.

The lesson is also real. Recurring themes in the compounded reports — dosing errors with concentrated multi-dose vials, product-quality questions, formulation surprises — are exactly the failure modes that FDA review of manufacturing exists to prevent and that pharmacy variance invites. This is the concrete meaning of "not FDA-approved" beyond legal boilerplate, and it's why our side-effects guide carries a compounded-specific section and every review runs the pharmacy questions. Report problems to FDA MedWatch; it is the mechanism by which this number means something.